AstraZeneca PLC (FRA:ZEG)

AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of EUR 271.22 billion. The enterprise value is 291.65 billion.

Market Cap	271.22B
Enterprise Value	291.65B

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Feb 19, 2026

Share Statistics

Current Share Class	1.55B
Shares Outstanding	n/a
Shares Change (YoY)	-0.06%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 31.14 and the forward PE ratio is 20.01.

PE Ratio	31.14
Forward PE	20.01
PS Ratio	5.42
PB Ratio	6.54
P/TBV Ratio	n/a
P/FCF Ratio	27.07
P/OCF Ratio	21.85
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.59, with an EV/FCF ratio of 29.11.

EV / Earnings	33.49
EV / Sales	5.84
EV / EBITDA	17.59
EV / EBIT	24.53
EV / FCF	29.11

Financial Position

The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.

Current Ratio	0.94
Quick Ratio	0.72
Debt / Equity	0.61
Debt / EBITDA	1.52
Debt / FCF	2.52
Interest Coverage	8.25

Financial Efficiency

Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.12%.

Return on Equity (ROE)	22.84%
Return on Assets (ROA)	8.01%
Return on Invested Capital (ROIC)	16.12%
Return on Capital Employed (ROCE)	16.75%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	530,520
Profits Per Employee	92,350
Employee Count	94,300
Asset Turnover	0.54
Inventory Turnover	1.82

Taxes

In the past 12 months, AstraZeneca has paid 1.85 billion in taxes.

Income Tax	1.85B
Effective Tax Rate	17.49%

Stock Price Statistics

The stock price has increased by +21.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+21.84%
50-Day Moving Average	160.73
200-Day Moving Average	141.20
Relative Strength Index (RSI)	60.75
Average Volume (20 Days)	1,224

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of EUR 50.03 billion and earned 8.71 billion in profits. Earnings per share was 5.57.

Revenue	50.03B
Gross Profit	40.85B
Operating Income	11.91B
Pretax Income	10.56B
Net Income	8.71B
EBITDA	16.60B
EBIT	11.91B
Earnings Per Share (EPS)	5.57

Balance Sheet

The company has 4.89 billion in cash and 25.30 billion in debt, with a net cash position of -20.41 billion.

Cash & Cash Equivalents	4.89B
Total Debt	25.30B
Net Cash	-20.41B
Net Cash Per Share	n/a
Equity (Book Value)	41.49B
Book Value Per Share	26.72
Working Capital	-1.61B

Cash Flow

In the last 12 months, operating cash flow was 12.41 billion and capital expenditures -2.39 billion, giving a free cash flow of 10.02 billion.

Operating Cash Flow	12.41B
Capital Expenditures	-2.39B
Free Cash Flow	10.02B
FCF Per Share	n/a

Margins

Gross margin is 81.66%, with operating and profit margins of 23.80% and 17.41%.

Gross Margin	81.66%
Operating Margin	23.80%
Pretax Margin	21.11%
Profit Margin	17.41%
EBITDA Margin	33.19%
EBIT Margin	23.80%
FCF Margin	20.03%

Dividends & Yields

This stock pays an annual dividend of 2.47, which amounts to a dividend yield of 1.38%.

Dividend Per Share	2.47
Dividend Yield	1.38%
Dividend Growth (YoY)	-15.62%
Years of Dividend Growth	4
Payout Ratio	48.62%
Buyback Yield	0.06%
Shareholder Yield	1.45%
Earnings Yield	3.21%
FCF Yield	3.69%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.21 and a Piotroski F-Score of 7.

Altman Z-Score	3.21
Piotroski F-Score	7